Consistently, a higher proportion of tumor‐infiltrating T cells exhibited expression of the T cell activation marker CD69 and effector molecules GZMB and IFNγ (Figure S6I, Supporting Information) in the combination treatment group as compared with to the control or single drug treatment group. This evidence concerns the gene GZMB and neoplasm.